VertiFlex
Date | Investors | Amount | Round |
---|---|---|---|
$28.3m | Series C | ||
N/A | $8.0m | Debt | |
$14.0m | Early VC | ||
N/A | $8.0m | Debt | |
N/A | $15.1m | Debt | |
$45.3m | Late VC | ||
$45.3m | Growth Equity VC | ||
N/A | Acquisition | ||
Total Funding | €121m |
Related Content
Recent News about VertiFlex
EditVertiflex, a subsidiary of Boston Scientific, specializes in developing and providing minimally invasive medical devices aimed at treating lumbar spinal stenosis, a condition that causes narrowing of the spinal canal and leads to pain and reduced mobility. The company primarily serves healthcare providers and patients in the medical device market, focusing on improving patient outcomes through advanced technology. Vertiflex's core product, the Superion Indirect Decompression System, is designed to offer a less invasive alternative to traditional spinal surgery, thereby reducing recovery times and associated risks. The business model revolves around the sale of these medical devices to hospitals, clinics, and healthcare professionals, generating revenue through product sales and ongoing support services. Vertiflex operates in a highly specialized segment of the medical device industry, leveraging innovation and clinical expertise to maintain a competitive edge.
Keywords: minimally invasive, spinal stenosis, lumbar, medical devices, healthcare, Superion, decompression, patient mobility, recovery, innovation.